Caja Costarricense de Seguro Social
14
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
Role: lead
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
Role: lead
Psoriasis Comorbidities at Hospital Calderón Guardia
Role: lead
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
Role: lead
Generalized Pustular Psoriasis Registry in Costa Rica
Role: lead
Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System
Role: lead
Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Hansen's Disease in Costa Rica (2018-2025)
Role: lead
A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.
Role: lead
Promoting Early Language Development Through Parent-child Book Reading in Costa Rica
Role: collaborator
Implementation of an Epidemiological and Clinical Registry of Emergency Surgery Patients in a Costa Rican Hospital
Role: lead
Primary Immunodeficiencies in Costa Rican Adults
Role: lead
Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients
Role: lead
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
Role: lead
Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica
Role: collaborator
All 14 trials loaded